RUBY — Rubius Therapeutics Share Price
0.000.00%
Last trade - 00:00- $5.16m
- -$9.71m
- 18
- 50
- 59
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.34 | ||
| Price to Tang. Book | 0.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1172.07% | ||
| Return on Equity | -185.31% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rubius Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company’s Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company’s subsidiary is Rubius Therapeutics Securities Corporation.
Directors
- David Epstein CHM (59)
- Pablo Cagnoni PRE (58)
- Jose Carmona CFO (49)
- Dannielle Appelhans COO (38)
- Laurence Turka CSO (63)
- Jim Jogerst OTH
- Maiken Keson-Brookes SEC (48)
- Noubar Afeyan IND
- Francis Cuss IND (66)
- Natalie Holles IND (48)
- Anne Prener IND (63)
- Michael Rosenblatt IND (74)
- Catherine Sohn IND (68)
- Jonathan Symonds IND (62)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- April 26th, 2013
- Public Since
- July 18th, 2018
- No. of Shareholders
- 13
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 90,482,951
- Address
- C/O VERDOLINO & LOWEY, FOXBORO, 02035
- Web
- https://www.rubiustx.com/
- Phone
- +1 6176799600
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for RUBY
Similar to RUBY
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Rubius Therapeutics share price?
As of Today at 18:18 UTC, shares in Rubius Therapeutics are trading at $0.06. This share price information is delayed by 15 minutes.
How has the Rubius Therapeutics share price performed this year?
Shares in Rubius Therapeutics last closed at $0.06 and the price had moved by -70.37% over the past 365 days. In terms of relative price strength the Rubius Therapeutics share price has underperformed the S&P500 Index by -75.21% over the past year.
What are the analyst and broker recommendations for Rubius Therapeutics?
The overall consensus recommendation for Rubius Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Rubius Therapeutics dividend yield?
Rubius Therapeutics does not currently pay a dividend.
Does Rubius Therapeutics pay a dividend?
Rubius Therapeutics does not currently pay a dividend.
When does Rubius Therapeutics next pay dividends?
Rubius Therapeutics does not currently pay a dividend.
How do I buy Rubius Therapeutics shares?
To buy shares in Rubius Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rubius Therapeutics?
As of the previous close price of $0.06, shares in Rubius Therapeutics had a market capitalisation of $5.16m.
Where are Rubius Therapeutics shares listed?
Here are the trading details for Rubius Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RUBY
What kind of share is Rubius Therapeutics?
Based on an overall assessment of its quality, value and momentum Rubius Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rubius Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Rubius Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rubius Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +156.09%.
As of the last closing price of $0.06, shares in Rubius Therapeutics were trading +187.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rubius Therapeutics PE Ratio?
The Rubius Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rubius Therapeutics?
Rubius Therapeutics' management team is headed by:
- David Epstein - CHM
- Pablo Cagnoni - PRE
- Jose Carmona - CFO
- Dannielle Appelhans - COO
- Laurence Turka - CSO
- Jim Jogerst - OTH
- Maiken Keson-Brookes - SEC
- Noubar Afeyan - IND
- Francis Cuss - IND
- Natalie Holles - IND
- Anne Prener - IND
- Michael Rosenblatt - IND
- Catherine Sohn - IND
- Jonathan Symonds - IND